GPCR (Structure Therapeutics Inc. American Depositary Shares)
Insider Trading Activity
Every open-market purchase and sale reported by GPCR officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-02 | Xichen Lin | CHIEF SCIENTIFIC OFFICER | MIXED | — | — |
| 2026-08-19 | Xichen Lin | CHIEF SCIENTIFIC OFFICER | MIXED | — | — |
| 2026-08-07 | John Joseph Berrios | Chief Commercial Officer | A | — | — |
| 2026-08-07 | John Joseph Berrios | Chief Commercial Officer | A | — | — |
| 2026-08-05 | Xichen Lin | CHIEF SCIENTIFIC OFFICER | MIXED | — | — |
| 2026-07-24 | FMR LLC | 10%+ Owner | Sell | — | — |
| 2026-07-15 | Xichen Lin | CHIEF SCIENTIFIC OFFICER | MIXED | — | — |
| 2026-06-29 | Xichen Lin | CHIEF SCIENTIFIC OFFICER | MIXED | — | — |
| 2026-06-18 | Joanne Waldstreicher | Director | A | — | — |
| 2026-06-18 | DANIEL G WELCH | Director | A | — | — |
| 2026-06-18 | TED W LOVE | Director | A | — | — |
| 2026-06-18 | ERIC DOBMEIER | Director | A | — | — |
| 2026-06-18 | Angus C. Russell | Director | A | — | — |
| 2026-06-18 | SHARON TETLOW | Director | A | — | — |
| 2026-04-23 | Matthew Lang | COO & GC | A | — | — |
| 2026-04-16 | FMR LLC | 10%+ Owner | Sell | — | — |
| 2026-03-23 | Ashley Hall | Chief Development Officer | A | — | — |
| 2026-03-23 | Crespo Blas Coll | CHIEF MEDICAL OFFICER | A | — | — |
| 2026-03-23 | Xichen Lin | CHIEF SCIENTIFIC OFFICER | A | — | — |
| 2026-03-23 | Yingli Ma | CHIEF TECHNOLOGY OFFICER | A | — | — |
| 2026-03-23 | Jun Yoon | CHIEF FINANCIAL OFFICER | A | — | — |
| 2026-03-23 | Raymond C Stevens | CHIEF EXECUTIVE OFFICER | A | — | — |
| 2026-03-05 | Xichen Lin | CHIEF SCIENTIFIC OFFICER | F | — | — |
| 2026-03-05 | Jun Yoon | CHIEF FINANCIAL OFFICER | F | — | — |
| 2026-03-05 | Crespo Blas Coll | CHIEF MEDICAL OFFICER | F | — | — |
| 2026-03-05 | Yingli Ma | CHIEF TECHNOLOGY OFFICER | F | — | — |
| 2026-03-05 | Raymond C Stevens | CHIEF EXECUTIVE OFFICER | F | — | — |
| 2026-03-05 | Ashley Hall | Chief Development Officer | F | — | — |
| 2026-01-20 | FMR LLC | 10%+ Owner | Sell | — | — |
| 2025-12-10 | FMR LLC | 10%+ Owner | Sell | — | — |
| 2025-09-22 | Ashley Hall | Chief Development Officer | F | — | — |
| 2025-09-22 | Crespo Blas Coll | CHIEF MEDICAL OFFICER | F | — | — |
| 2025-08-20 | Yingli Ma | CHIEF TECHNOLOGY OFFICER | F | — | — |
| 2025-08-20 | Xichen Lin | CHIEF SCIENTIFIC OFFICER | F | — | — |
| 2025-08-01 | FMR LLC | 10%+ Owner | Sell | — | — |
| 2025-07-03 | Yingli Ma | CHIEF TECHNOLOGY OFFICER | MIXED | — | — |
| 2025-07-03 | Raymond C Stevens | CHIEF EXECUTIVE OFFICER | MIXED | — | — |
| 2025-07-03 | Xichen Lin | CHIEF SCIENTIFIC OFFICER | MIXED | — | — |
| 2025-07-03 | Jun Yoon | CHIEF FINANCIAL OFFICER | MIXED | — | — |
| 2025-07-03 | Crespo Blas Coll | CHIEF MEDICAL OFFICER | MIXED | — | — |
| 2025-06-25 | SHARON TETLOW | Director | A | — | — |
| 2025-06-25 | ERIC DOBMEIER | Director | A | — | — |
| 2025-06-25 | Joanne Waldstreicher | Director | A | — | — |
| 2025-06-25 | TED W LOVE | Director | A | — | — |
| 2025-06-25 | DANIEL G WELCH | Director | A | — | — |
| 2025-06-25 | Angus C. Russell | Director | A | — | — |
| 2025-03-18 | Xichen Lin | CHIEF SCIENTIFIC OFFICER | A | — | — |
| 2025-03-18 | Crespo Blas Coll | Chief Medical Officer | A | — | — |
| 2025-03-18 | Yingli Ma | CHIEF TECHNOLOGY OFFICER | A | — | — |
| 2025-03-18 | Raymond C Stevens | CHIEF EXECUTIVE OFFICER | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 3,260,495 | — |
| — | CHIEF FINANCIAL OFFICER | 2,956,242 | — |
| — | CHIEF EXECUTIVE OFFICER | 2,956,179 | — |
| — | — | 624,239 | — |
| — | CHIEF MEDICAL OFFICER | 280,878 | — |
| — | 10%+ Owner | 241,275 | — |
| — | CHIEF SCIENTIFIC OFFICER | 228,960 | — |
| — | COO & GC | 184,614 | — |
| — | Chief Development Officer | 155,187 | — |
| — | Chief Commercial Officer | 140,766 | — |
| — | CHIEF TECHNOLOGY OFFICER | 139,917 | — |
| — | Director | 123,508 | — |
| — | CHIEF MEDICAL OFFICER | 26,235 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the GPCR quote page; the site-wide leaderboard is on the insider transactions hub.